Piper Sandler restated their overweight rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research report released on Monday, Benzinga reports. Piper Sandler currently has a $270.00 price objective on the stock.
Other analysts also recently issued reports about the stock. Jefferies Financial Group raised their target price on shares of Praxis Precision Medicines from $75.00 to $128.00 and gave the stock a buy rating in a report on Tuesday, March 26th. Truist Financial restated a buy rating and set a $150.00 target price on shares of Praxis Precision Medicines in a report on Thursday, May 16th. Needham & Company LLC started coverage on shares of Praxis Precision Medicines in a report on Monday, June 24th. They set a buy rating and a $145.00 target price on the stock. Guggenheim started coverage on shares of Praxis Precision Medicines in a report on Tuesday, June 18th. They set a buy rating and a $155.00 target price on the stock. Finally, HC Wainwright restated a buy rating and set a $105.00 target price on shares of Praxis Precision Medicines in a report on Tuesday, May 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $137.38.
Read Our Latest Research Report on PRAX
Praxis Precision Medicines Price Performance
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($2.84) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($0.83). Praxis Precision Medicines had a negative return on equity of 101.99% and a negative net margin of 5,711.85%. The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $2.75 million. As a group, analysts predict that Praxis Precision Medicines will post -10.13 EPS for the current fiscal year.
Institutional Trading of Praxis Precision Medicines
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Simplex Trading LLC acquired a new position in Praxis Precision Medicines during the fourth quarter worth $31,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Praxis Precision Medicines by 45.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 56,130 shares of the company’s stock worth $96,000 after buying an additional 17,428 shares during the last quarter. Citigroup Inc. increased its holdings in Praxis Precision Medicines by 44,585.5% during the third quarter. Citigroup Inc. now owns 83,115 shares of the company’s stock worth $142,000 after buying an additional 82,929 shares during the last quarter. SG Americas Securities LLC acquired a new position in Praxis Precision Medicines during the first quarter worth $150,000. Finally, DLD Asset Management LP acquired a new position in Praxis Precision Medicines during the fourth quarter worth $223,000. 67.84% of the stock is currently owned by institutional investors and hedge funds.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Further Reading
- Five stocks we like better than Praxis Precision Medicines
- Buy P&G Now, Before It Sets A New All-Time High
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- ESG Stocks, What Investors Should Know
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.